Lirilumab: Phase II ongoing

An independent DSMB recommended for the fifth time continuation of double-blind, placebo-controlled, French Phase II EffiKIR trial evaluating 0.1 and 1 mg/kg lirilumab based on a safety analysis. Last year, the trial completed enrollment of about 150 patients. In March, the DSMB recommended stopping treatment in an undisclosed arm (see BioCentury, April 13). ...